Proteologix’s antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma.
Trending
- NMA warns of doctors’ burnout, premature deaths
- COANSA calls for better agricultural funding
- Ebonyi Senator distributes 10,000 bags of fertiliser
- Experts urge responsible AI use to tackle vaccine misinformation
- Nigeria seeks climate finance for key sectors
- Nigeria’s inflation drops to 14.63%, reserves hit $55bn — CBN
- EIB Global, FCMB commit €85m to Nigeria’s cocoa, dairy value chains
- Niger female town planners warn poor urban planning can worsen flooding, insecurity
